Thinly traded nano cap CNS Pharmaceuticals (NASDAQ:CNSP) jumps 22% premarket on average volume in reaction to its announcement that
research performed at the University of Frankfurt showed the
2-deoxy-D-glucose (2-DG) totally blocked replication of SARS-CoV-2, the
virus causing COVID-19, in a cell culture model.
The findings were submitted to NatureResearch about a month ago.
The company is collaborating with WPD Pharmaceuticals (OTCPK:WCOTF)
on development of WP112, a prodrug of 2-DG that may have therapeutic
potential in COVID-19 since 2-DG inhibits glycolysis which prevents the
coronavirus from replicating. In its normal state, though, it is
metabolized too quickly to be effective. WP112 is only metabolized once
it is inside the cell, enabling much higher tissue and organ
concentrations of 2-DG.
https://seekingalpha.com/news/3560100-cns-pharma-up-22-premarket-on-2-dg-action-against-coronavirus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.